advertisement
Glaucoma Dialogue IGR 2-1
There is no Glaucoma Dialogue in this issue
A Glaucoma Dialogue is available for the following issues:
- 24-1: Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma
- 22-1: Impaired TRPV4-eNOS signaling in trabecular meshwork elevates intraocular pressure in glaucoma
- 21-2: Reprogramming to recover youthful epigenetic information and restore vision
- 20-4: Review of hygiene and disinfection
Recommendations for outpatient glaucoma care: A COVID era update
- 18-3: Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice
- 18-2: Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial
- 18-1: Validity of the Monocular Trial of Intraocular Pressure-Lowering at Different Time Points in Patients Starting Topical Glaucoma Medication
- 17-4: Structural and Functional Progression in the Early Manifest Glaucoma Trial
- 17-3: Fast circulation of cerebrospinal fluid: an alternative perspective on the protective role of high intracranial pressure in ocular hypertension
- 16-3: Induced pluripotent stem cells restore function in a human cell loss model of open-angle glaucoma
- 16-1: Glucose-induced temporary visual recovery in primary open-angle glaucoma: a double-blind, randomized study
- 15-2: Do findings on routine examination identify patients at risk for primary open-angle glaucoma? The rational clinical examination systematic review
- 15-1: Longitudinal hemodynamic changes within the optic nerve head in experimental glaucoma
- 14-3: Subspecialization in glaucoma surgery
- 14-2: Reduction in Intraocular Pressure after Cataract Extraction: The Ocular Hypertension Treatment Study
- 14-1: Cost-effectiveness of Medications Compared With Laser Trabeculoplasty in Patients With Newly Diagnosed Open-Angle Glaucoma
- 13-4: Retinal Ganglion Cell Layer Thickness and Local Visual Field Sensitivity in Glaucoma
- 13-3: Aqueous humor dynamics during the day and night in volunteers with ocular hypertension
- 13-1: A Randomized Trial of Brimonidine Versus Timolol in Preserving Visual Function: Results From the Low-pressure Glaucoma Treatment Study
- 12-4: Treating patients presenting with advanced glaucoma - Should we reconsider current practice?
- 12-3: Transscleral diode laser cycloablation in patients with good vision
- 12-2: Adenoviral gene transfer of active human transforming growth factor-{beta}2 elevates intraocular pressure and reduces outflow facility in rodent eyes
- 12-1: Optical coherence tomography quantitative analysis of iris volume changes after pharmacologic mydriasis
- 11-4: Three-year follow-up of the tube versus trabeculectomy study
- 11-3: Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma
- 11-2: Axonal regeneration induced by repetitive electrical stimulation of crushed optic nerve in adult rats
- 11-1: Effect of brimonidine on retinal ganglion cell survival in an optic nerve crush model
- 10-4: Disc hemorrhages and treatment in the early manifest glaucoma trial
- 10-3: The additional yield of a periodic screening programme for open-angle glaucoma: A population-based comparison of incident glaucoma cases detected in regular ophthalmic care with cases detected during screening
- 10-2: Cerebrospinal fluid pressure is decreased in primary open-angle glaucoma
- 10-1: Cost-effectiveness of treating ocular hypertension
- 9-4: Predictors of long-term progression in the Early Manifest Glaucoma Trial
- 9-3: Targeting amyloid-β in glaucoma treatment
